Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Cystinosis Research Foundation Awards $1.47 Million in Research Grants
  • USA - English


News provided by

Idea Hall

Sep 28, 2016, 08:00 ET

Share this article

Share toX

Share this article

Share toX

IRVINE, Calif. (PRWEB) September 28, 2016 -- The Cystinosis Research Foundation, the largest provider of grants for cystinosis research in the world, announced today that it has awarded $1.47 million to date this year in grants to researchers in four countries in an ongoing quest to find improved treatments and a cure for the disease.

Cystinosis is a rare, incurable metabolic disorder that afflicts 500 children and young adults in the United States and only 2,000 people worldwide. It slowly destroys the organs in the body including the kidneys, liver, eyes, muscles and brain due to a buildup of amino acid cystine that crystallizes and kills the cells.

This year’s grants, supported through donations from the 2016 Natalie’s Wish fundraising gala, are supporting research in the United States, New Zealand, France and Italy.

“We are deeply grateful to everyone who helped fund these new grants and ongoing research projects,” said CRF Founder Nancy Stack. “Every dollar donated to our organization for research goes to fund research grants. We are working together to ensure that the cycle of research continues at a rapid pace and that CRF funded researchers collaborate in an effort to accelerate research discoveries. We are on the brink of new treatments and are getting closer to a cure.”

Since 2003, the Cystinosis Research Foundation has raised $35 million for scientific studies into the cause and treatments of the disease, supporting 143 studies in 12 countries. Among other advancements in the study of the disease, CRF funded the development of a delayed-release medication approved in 2013 by the FDA. Ongoing research, in addition to studies funded this year, includes an allogeneic stem cell transplantation trial at UCLA, which is bringing the organization tantalizingly close to a cure.

“CRF has issued many grants that the National Institutes of Health or other large agencies would typically not fund because of the very small population of patients with this disease,” Stack said. “However, by providing researchers seed money, we have been able to leverage our research dollars by over $7 million in grants from the NIH and other granting agencies. We may be small in numbers, but we are big on achieving results. Much of the research funded through our organization has not only helped cystinosis patients, but has also led to advancements in the treatment of other diseases such as Huntington’s disease and Parkinson’s disease.

This year’s research grant awards support nine studies in four countries. They include:

United States
The Scripps Research Institute, La Jolla, California
• $75,000 to Sergio Catz, Ph.D., and Jinzhong Zhang, Ph.D., “Improvement of Cellular Function through Chaperone-Mediated Autophagy and Cellular Trafficking in Cystinosis.”

University of California, San Diego, California
• $160,589, (a two-year grant), to Ilya Gertsman, Ph.D., and Bruce Barshop, M.D. “Elucidation of Altered Metabolism and Biomarkers in Cystinosis.”
• $67,582 to Stephanie Cherqui, Ph.D., “Stem Cell Research Associate Support.”

University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
• $155,484 to Morgan Fedorchak, Ph.D., and Kanwal Nischal, M.D., FRCO, “Development of a Topical, Controlled Release Cysteamine Eye Drop.”

Massachusetts General Hospital, Boston, Massachusetts
• $96,129 to Florian Eichler, M.D., and Sherman Alexander, M.Sc., “Clinical Trial Readiness for Distal Myopathy in Nephropathic Cystinosis.”

Harvard Medical School, Boston, Massachusetts
• $225,000 (a three-year grant) to Norbert Perrimon, Ph.D., and Patrick Jouandin, Ph.D., “Profiling Metabolic Dysfunction Caused by Cystinosis.”

France
Paris Descartes University, France
• $225,000 (a three-year grant) to Bruno Gasnier, Ph.D., and Yann Terres, M.Sc., “Mechanism and Pathophysiological Significances of a Genetic Interaction of Cystinosin.”

Italy
Bambino Gesù Children’s Hospital, Rome, Italy
• $180,400 to Giusi Pencipe, Ph.D., and Fabrizio De Benedetti, M.D., Ph.D., “NLRP2 in the Pathogenesis of Cystinosis.”

New Zealand
The University of Auckland, New Zealand
• $145,852 (a two-year grant) to Alan Davidson, Ph.D., and Teresa Holm, Ph.D., M.D., “Kidney Organoids: A New Model to Study Cystinosis.”

About the Cystinosis Research Foundation
The Cystinosis Research Foundation is dedicated to finding better treatments to improve the quality of life for those with cystinosis and to ultimately find a cure for this devastating disease. Since 2003, it has raised and committed more than $35 million to support bench, clinical and translational research to find better treatments and a cure for cystinosis. The foundation is dedicated to educating the public and medical community about cystinosis to ensure early diagnosis and proper treatment. Visit us on Facebook or http://www.cystinosisresearch.org.

Deniene Rivenburg, Idea Hall, +1 714-263-8751, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.